

(43) International Publication Date 8 March 2001 (08.03.2001)

PCT

(10) International Publication Number WO 01/16318 A3

(51)	International Pate	ent Classification7:	C12N 1:			PCT/US00/04414	22 February 2000 (22.02.2000)	US
	C07K 14/47, 14/70	5, G01N 33/53, C13	2N 15/62, C07	K		DCTT// 1000/05401	1 March 2000 (01.03.2000)	US
	16/18		•			PCT/US00/05601	3 March 2000 (03.03.2000)	· US
			DOTH ICOOK	2220		60/187.202 60/191,007	21 March 2000 (21.03.2000)	US
(21)	International App	dication Number:	PCT/US00/2	20040		PCT/US00/08439	30 March 2000 (30.03.2000)	US
		- Data 24 August	2000 (24 08	2000)		60/199,397	25 April 2000 (25.04.2000)	US
(22)	International Filin	1 2000 (24.06.	(24.08.2000)		PCT/US00/14042	22 May 2000 (22.05.2000)	US	
	Filing Language: Englis					60/209,832	5 June 2000 (05.06.2000)	US
(25)	Filing Language:		1.51	ignan		00/209,032	5 Julie 2000 (0.7.00.2000)	-
(36)	Dublication Langu	u.0.46*	E	nglish	(71)	Applicant (for all	designated States except US): GE	NEN-
(20)	Publication Lange	uage.			(,1)	TECH. INC. (US/	US]; I DNA Way, South San Fran	cisco,
(30)	Priority Data:					CA 94080-4990 (U		
(30)	PCT/US99/20111	*					•	
	1 (1/03/)/20111	1 September 1999	(01.09.1999)	US	(72)	Inventors; and		
	PCT/US99/21090	1 ooptomeer tree	,		(75)	Inventors/Applica	ants (for US only): EATON,	Dan,
	101/03/2/2/070	15 September 1999	(15.09,1999)	US	• ,	L. [US/US]; 75	Knight Drive, San Rafael, CA !	94901
	60/169,495	7 December 1999				(US). FILVAROI	FF, Ellen [US/US]: 538 18th Av	venue,
	60/170,262	9 December 1999	(09.12.1999)	US	_	San Francisco, C	A 94121 (US). GERRITSEN,	Mary,
	60/175,481	11 January 2000		US		E. [CA/US]; 541	Parrott Drive, San Mateo, CA	94402
	PCT/US00/04341	***************************************	,			(US). GODDARI), Audrey [CA/US]; 110 Congo	Street,
	1 617 63 667 673 77	18 February 2000	(18.02.2000)	US		San Francisco, C	CA 94131 (US). GODOWSKI,	Paul.
	PCT/US00/04342	•				J. [US/US]; 2627	Easton Drive, Burlingame, CA	94010
	101,0000001010	18 February 2000	(18.02.2000)	US		(US). GRIMALD	I, Christopher, J. [US/US]; 143	4 36th
		•		"			[Continued on next	page

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

<subunit 1 of 1, 266 aa, 1 stop <MW: 29766, pI: 8.39, NX(S/T): 0

MWWFQQGLSFLPSALVIWTSAAFIFSYITAVTLHHIDPALPYISDTGTVAPEKCLFGAMLNIA
AVLCIATIYVRYKQVHALSPEENVIIKLNKAGLVLGILSCLGLSIVANFQKTTLFAAHVSGAV
LTFGMGSLYMFVQTILSYQMQPKIHGKQVFWIRLLLVIWCGVSALSMLTCSSVLHSGNFGTDL
EQKLHWNPEDKGYVLHMITTAAEWSMSFSFFGFFLTYIRDFQKISLRVEANLHGLTLYDTAPC
PINNERTRLLSRDI

Important features:

Type II transmembrane domain:

amino acids 13-33

Other Transmembrane domains:

amino acids 54-73, 94-113, 160-180, 122-141

N-myristoylation sites.

amino acids 57-63, 95-101, 99-105, 124-130, 183-189

(57) Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.



Avenue, San Francisco, CA 94122 (US). GURNEY, Austin, L. [US/US]: I Debbie Lane, Belmont, CA 94002 (US). WATANABE, Colin, K. [US/US]: 128 Corliss Drive, Moraga, CA 94556 (US). WOOD, William, I. [US/US]: 35 Southdown Court, Hillsborough, CA 94010 (US).

- (74) Agents: KRESNAK, Mark, T. et al.; Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description
- (88) Date of publication of the international search report: 29 November 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

International Application No PCT/US 00/23328

A. CLASSIFICATION OF SUBJECT MATTER
1PC 7 C12N15/12 C07K14/47 G01N33/53 C07K14/705 C12N15/62 C07K16/18 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N CO7K G01N IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category ° WO 99 25825 A (BOUGUELERET LYDIE :GENSET 1-20 Χ SA (FR); DUCLERT AYMERIC (FR); DUMAS MIL) 27 May 1999 (1999-05-27) the whole document WO 99 24836 A (ENDRESS GREGORY A ; HUMAN 1-20 χ GENOME SCIENCES INC (US); FENG PING (US);) 20 May 1999 (1999-05-20) the whole document EP 0 834 563 A (SMITHKLINE BEECHAM CORP) Α 8 April 1998 (1998-04-08) the whole document WO 97 07198 A (GENETICS INST) Α 27 February 1997 (1997-02-27) the whole document -/--Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents: T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled "P" document published prior to the international filing date but later than the priority date claimed in the art. "8" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 2 3, 04, 01 24 January 2001 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Riiswiik Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Smalt, R

Fax: (+31-70) 340-3016

1

International Application No
PCT/US 00/23328

Relevant to claim No. L: "A signal using secreted indicator" AL PRESS. 3), pages ION FOR GENES AND RECEPTORS" AL ACADEMY OF AL ACADEMY AL ACADEMY OF AL ACADEMY AL AC
using secreted addicator" AL PRESS. Solve For Genes and Receptors" AL ACADEMY OF AL A
S AND RECEPTORS" AL ACADEMY OF AL ACADEMY OF 996 (1996-07-09), H11 N ; CHEN JIAN YUAN JEAN (US); 12-09)
YUAN JEAN (US); 12-09)
1 20
1-20 9-16)
(NC) 1-20 07)
J

International application No. PCT/US 00/23328

INTERNATIONAL SEARCH REPORT

Box i	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 35-38, in as far as they pertain to in vivo methods, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Claims 1-20 (all partially).
Remar	k on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Continuation of Box I.2

Present claims 21-38 relate to a polypeptide, designated F or PRO1, which is not characterized in the description. This gives rise to a lack of clarity within the meaning of Article 6 PCT to such an extent as to render a meaningful search of the claims in respect of said protein impossible. Consequently, the search has been limited to the remaining parts of the claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: 1-20, all partially

PRO180: nucleic acid with seq.ID.1, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.2 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.2 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide.

2. Claims: Inventions 2-76: claims 1-20, all partially

```
Subject matter as defined for invention 1, but related to
the respective nucleic acid/polypeptide sequences of:
2. PRO218, represented by seq.ID.s 3 and 4,
3. PRO263, represented by seq.ID.s 5 and 6, 4. PRO295, as represented by seq.ID's 7 and 8
5. PRO874, as represented by seq.ID's 9 and 10, 6. PRO300, as represented by seq.ID's 11 and 12
7. PRO1864, as represented by seq.ID's 13 and 14,
8. PRO1282, as represented by seq.ID's 15 and 16,
9. PRO1063, as represented by seq.ID's 17 and 18,
10.PR01773, as represented by seq.ID's 19 and 20,
11.PRO1013, as represented by seq.ID's 21 and 22,
12.PRO937, as represented by seq.ID's 23 and 24,
13.PRO842, as represented by seq.ID's 25 and 26,
14.PRO1180, as represented by seq.ID's 27 and 28,
15.PRO831, as represented by seq.ID's 29 and 30,
16.PRO1115, as represented by seq.ID's 31 and 32,
17.PRO1277, as represented by seq.ID's 33 and 34,
18.PRO1074, as represented by seq.ID's 35 and 36,
19.PRO1344, as represented by seq.ID's 37 and 38,
20.PRO1136, as represented by seq.ID's 39 and 40,
21.PRO1109, as represented by seq.ID's 41 and 42,
22.PRO1003, as represented by seq.ID's 43 and 44,
23.PRO1138, as represented by seq.ID's 45 and 46,
24.PR0994, as represented by seq.ID's 47 and 48, 25.PR01069, as represented by seq.ID's 49 and 50,
26.PRO1411, as represented by seq.ID's 51 and 52,
27.PRO1129, as represented by seq.ID's 53 and 54,
28.PRO1027, as represented by seq.ID's 55 and 56,
29.PRO1106, as represented by seq.ID's 57 and 58,
 30.PR01291, as represented by seq.ID's 59 and 60,
 31.PRO3573, as represented by seq.ID's 61 and 62,
 32.PRO3566, as represented by seq.ID's 63 and 64,
 33.PR01098, as represented by seq.ID's 65 and 66,
 34.PR01158, as represented by seq.ID's 67 and 68,
 35.PR01124, as represented by seq.ID's 69 and 70,
```

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210 36.PR01278, as represented by seq.ID's 71 and 72, 37.PR01335, as represented by seq.ID's 73 and 74, 38.PR01315, as represented by seq.ID's 75 and 76, 39.PRO1357, as represented by seq.ID's 77 and 78. 40.PR01356, as represented by seq.ID's 79 and 80, 41.PR01557, as represented by seq.ID's 81 and 82, 42.PR01347, as represented by seq.ID's 83 and 84, 43.PR01302, as represented by seq.ID's 85 and 86, 44.PR01270, as represented by seq.ID's 87 and 88, 3. Claim: Invention 45.PR01268, as represented by seq.ID's 89 and 90, 46.PR01327, as represented by seq.ID's 91 and 92. 47.PR01328, as represented by seq.ID's 93 and 94, 48.PR01329, represented by seq.ID.s 95 and 96, 49.PR01340, as represented by seq.ID's 97 and 98. 50.PR01342, as represented by seq.ID's 99 and 100. 51.PR03579, as represented by seq.ID's 101 and 102, 52.PR01472, as represented by seq.ID's 103 and 104, 53.PR01461, as represented by seq.ID's 105 and 106, 54.PR01568, as represented by seq.ID's 107 and 108, 55.PR01753, as represented by seq.ID's 109 and 110, 56.PR01570, as represented by seq.ID's 111 and 112, 57.PR01446, as represented by seq.ID's 113 and 114, 58.PR01565, as represented by seq.ID's 115 and 116, 59.PR01572, as represented by seq.ID's 117 and 118. 60.PR01573, as represented by seq.ID's 119 and 120. 61.PR01550, as represented by seq.ID's 121 and 122. 62.PR01693, as represented by seq.ID's 123 and 124. 63.PR01566, as represented by seq.ID's 125 and 126, 64.PR01774, as represented by seq.ID's 127 and 128, 65.PR01928, as represented by seq.ID's 129 and 130. 66.PR01865, as represented by seq.ID's 131 and 132, 67.PR01925, as represented by seq.ID's 133 and 134, 68.PR01926, as represented by seq.ID's 135 and 136, 69.PR01801, as represented by seq.ID's 137 and 138, 70.PRO4405, as represented by seq.ID's 139 and 140, 71.PRO3435, as represented by seq.ID's 141 and 142, 72.PR03543, as represented by seq.ID's 143 and 144, 73.PRO3443, as represented by seq.ID's 145 and 146,

For the sake of conciseness, the first subject matter is explicitly defined, the subject matter of inventions 2-76 are defined by analogy thereto.

4. Claims: Invention 77: claims 1-3,5-12,14-38, all partially

PRO10272: nucleic acid with seq.ID.155, encoding a polypeptide comprising the amino acid sequence as

74.PRO3442, as represented by seq.ID's 147 and 148, 75.PRO5990, as represented by seq.ID's 149 and 150, and 76.PRO4342, as represented by seq.ID's 151 and 152.

represented in seq.ID.156 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.156 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PR010272 using its interaction with PR05801 (seq.ID.158), method for linking a bioactive molecule to a cell expressing PR010272 through the use of PR05801, and method of modulating at least one activity of said cell thereby.

5. Claims: Invention 78: claims 1-3,5-12,14-38, all partially

PRO20110: nucleic acid with seq.ID.159, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.160 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.160 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO20110 using its interaction with PRO20040 (seq.ID.162), method for linking a bioactive molecule to a cell expressing PRO20110 through the use of PRO20040, and method of modulating at least one activity of said cell thereby.

6. Claims: Invention 79: claims 1-3,5-12,14-38, all partially

PRO10096: nucleic acid with seq.ID.153, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.154 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.154 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PR010096 using its interaction with PR020233 (seq.ID.164), method for linking a bioactive molecule to a cell expressing PR010096 through the use of PR020233, and method of modulating at least one activity of said cell thereby.

7. Claims: Invention 80: claims 1-3,5-12,14-38, all partially

PR019670: nucleic acid with seq.ID.165, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.166 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.166 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PR019670 using its interaction with PR01890 (seq.ID.168), method for linking a bioactive molecule to a cell expressing PR019670 through the use of PR01890, and method of modulating at least one activity of said cell thereby.

8. Claims: Invention 81: claims 1-3,5-12,14-38, all partially

PR05801: nucleic acid with seq.ID.157, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.158 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.158 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PR05801 using its interaction with PR010272 (seq.ID.156), method for linking a bioactive molecule to a cell expressing PR05801 through the use of PR010272, and method of modulating at least one activity of said cell thereby.

9. Claims: Invention 82: claims 1-3,5-12,14-38, all partially

PRO20040: nucleic acid with seq.ID.161, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.162 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.162 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO20040 using its interaction with PRO20110 (seq.ID.160), method for linking a bioactive molecule to a cell expressing PRO20040 through the use of PRO20110, and method of modulating at least one activity of said cell thereby.

10. Claims: Invention 83: claims 1-3,5-12,14-38, all partially

PR020233: nucleic acid with seq.ID.163, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.164 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.164 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PR020233 using its interaction with PR010096 (seq.ID.154), method for linking a bioactive molecule to a cell expressing PR020233 through the use of PR010096, and method of modulating at least one activity of said cell thereby.

11. Claims: Invention 84: claims 1-3,5-12,14-38, all partially

PRO1890: nucleic acid with seq.ID.167, encoding a polypeptide comprising the amino acid sequence as represented in seq.ID.168 or a nucleic acid having at least 80% homology thereto, vector comprising said nucleic acid, host cell comprising said vector, process for producing the protein of seq.ID.168 using said host, the isolated protein or one having at least 80% homology thereto, a chimeric protein of said peptide fused to a heterologous sequence, isolated extracellular domain of said protein or said protein lacking its signal peptide, and an antibody against said polypeptide. Also a method of detecting PRO1890 using its interaction with PRO19679 (seq.ID.166), method for linking a bioactive molecule to a cell expressing PRO1890 through the use of PRO19679, and method of modulating at least one activity of said cell thereby.

Information on patent family members

PCT/US 00/23328

						00/23328
	itent document in search report		Publication date		Patent family member(s)	Publication date
WO	9925825	A	27-05-1999	AU EP AU EP WO AU EP WO	1049199 A 1029045 A 1503099 A 1037977 A 9931236 A 2294499 A 1053318 A 9940189 A	07-06-1999 23-08-2000 05-07-1999 27-09-2000 24-06-1999 23-08-1999 22-11-2000 12-08-1999
WO	9924836	A	20-05-1999	AU EP AU	1303799 A 1032838 A 1303199 A	31-05-1999 06-09-2000 31-05-1999
EP	0834563	A	08-04-1998	JP US	10179178 A 5824504 A	07-07-1998 20-10-1998
WO	9707198	A	27-02-1997	US AU AU AU CA CA EP EP JP US WO US	5707829 A 727480 B 6712396 A 727489 B 6768596 A 2227220 A 2229208 A 0839196 A 0851875 A 11510045 T 6043344 A 9704097 A 6074849 A 5969093 A	13-01-1998 14-12-2000 18-02-1997 14-12-2000 12-03-1997 06-02-1997 27-02-1997 06-05-1998 08-07-1998 07-09-1999 28-03-2000 06-02-1997 13-06-2000 19-10-1999
MO	9963088	A	09-12-1999	AU AU WO	4328699 A 2212299 A 9935170 A	20-12-1999 26-07-1999 15-07-1999
WO	9946287	Α	16-09-1999	AU EP	2997299 A 1062233 A	27-09-1999 27-12-2000
WO	0073454	A	07-12-2000	AU AU AU AU AU AU WO WO WO WO WO WO WO	1748200 A 1932000 A 2192800 A 2495200 A 2600800 A 3381600 A 3514400 A 4328699 A 0053755 A 0053755 A 0053757 A 0053757 A 0053758 A 0073445 A 0073445 A 0073452 A 0032221 A 0036102 A 0037640 A 0075316 A	19-06-2000 03-07-2000 12-07-2000 28-09-2000 28-09-2000 28-09-2000 28-09-2000 20-12-1999 14-09-2000 14-09-2000 14-09-2000 14-09-2000 07-12-2000 07-12-2000 07-12-2000 08-06-2000 29-06-2000 14-12-2000

Information on patent family members

International Application No PCT/US 00/23328

1	date	Patent family member(s)		Publication date
WO 0073454 A		AU	2883600 A	28-09-2000
NO 0070101		WO	0053756 A	14-09-2000
		WO	0078961 A	28-12-2000
		WO	0104311 A	18-01-2001
		AU	1749800 A	04-10-2000
		AU	1749900 A	12-07-2000
		AU	2399300 A	28-09-2000
		AU	3107000 A	19-06-2000
		WO	0105972 A	25-01-2001
		WO	0032778 A	08-06-2000
		WO	0055319 A	21-09-2000
		WO	0037638 A	29-06-2000
		WO	0105836 A	25-01-2001
		WO	0053751 A	14-09-2000
		MO	0077037 A	21-12-2000
		WO	0109327 A	08-02-2001
		WO	0075317 A	14-12-2000
		AU	5922999 A	03-04-2000
		WO	0118210 A	15-03-2001
!		WO	0116318 A .	08-03-2001
		WO	0119987 A	22-03-2001
		AU	6498499 A	03-04-2000
•		WO	0119991 A	22-03-2001
		AU	2224800 A	28-09-2000
		AU	2596700 A	28-09-2000
		AU	3107700 A	28-09-2000
		WO WO	0053754 A 0053750 A	14-09-2000 14-09-2000
		AU	0053750 A 2474700 A	19-06-2000